Exterior presumption of the entranceway to Merck office connected February 05, 2024 successful Rahway, New Jersey.
Spencer Platt | Getty Images
Merck volition get Cidara Therapeutics successful a astir $9.2 cardinal deal, the companies said connected Friday, gaining entree to an experimental cause for flu prevention.
Merck is looking to diversify its gross beyond Keytruda arsenic its patents for the blockbuster cause commencement to expire aboriginal this decade.
Since 2021, the institution has astir tripled its late-stage pipeline, combining in-house improvement with deals specified arsenic the $11.5 billion acquisition of Acceleron successful 2021, which netted the pulmonary arterial hypertension cause Winrevair.
In July, Merck signed its $10 cardinal buyout of UK-based Verona Pharma, gaining Ohtuvayre, a recently approved cause for chronic obstructive pulmonary disease, commonly known arsenic "smoker's lung".
Cidara is processing its long-acting antiviral cause CD388, which has the imaginable to beryllium a single-dose, cosmopolitan prevention against each flu strains.
English (US) ·